KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Long-term follow-up of predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia in the phase 3 COMMODORE trial.

Bin Jiang, Jian Li, Ligen Liu, Xin Du, Hao Jiang, Jianda Hu, Xiaoxi Zeng, Taishi Sakatani, Masanori Kosako, Yaru Deng, Vladimir Ivanov, Sergey Bondarenko, Lily Wong Lee Lee, Archrob Khuhapinant, Elena Martynova, Nahla Hasabou, Jamie Jung-Hee An, Jianxiang Wang

Ann Hematol 105(1) 3

PMID41521262
PMCIDPMC12791058
DOI10.1007/s00277-026-06762-2
发表日期2026-01-11
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

To evaluate the long-term efficacy and safety of gilteritinib compared with salvage chemotherapy (SC) in patients with relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML). In the phase 3 COMMODORE (NCT03182244) trial, patients with relapsed/refractory FLT3-mutated AML from China, Russia, Singapore, Thailand, and Malaysia were randomized to gilteritinib (120 mg/day) or SC. The long-term follow-up included assessments every 3 months for a maximum of 3 years from the end-of-treatment visit. The primary endpoint was overall survival (OS). Secondary endpoints included event-free survival (EFS), complete remission (CR) rate, hematopoietic stem cell transplantation (HSCT) rate, and transfusion maintenance and conversion rates. Overall, 276 patients (gilteritinib, n = 137; SC, n = 139) completed the long-term follow-up. Most (88.0%) patients were Asian. The median (95% confidence interval [CI]) OS was longer with gilteritinib versus SC (10.3 [8.8, 12.7] vs 5.4 [4.1, 8.1] months, respectively; hazard ratio [HR; 95% CI], 0.612 [0.451, 0.832]), with a median follow-up of 34.6 months. The median (95% CI) EFS was longer with gilteritinib versus SC (2.1 [< 0.1, 3.2] vs 0.6 [0.2, 1.2] months, respectively; HR [95% CI], 0.589 [0.438, 0.792]). The CR rate was 20.4% and 11.5% in the gilteritinib and SC arms, respectively. During the entire study period, 22.6% and 7.9% of patients in the gilteritinib and SC arms underwent HSCT, respectively; 18.2% of patients in the gilteritinib arm received on-study HSCT. No new safety concerns were identified. Long-term gilteritinib treatment improved clinical outcomes compared with SC and was well-tolerated in a predominantly Asian population with relapsed/refractory FLT3-mutated AML.

KM 提取结果

2 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure2 个面板

Fig. 2

Fig. 2 Kaplan-Meier analysis of OS by treatment arm ( a ) and censored at HSCT ( b ). P value is from a stratified 2-sided log-rank test. Survival rates and 95% CIs were estimated using the Kaplan-Meier method and Greenwood formula. CI, confidence interval; HR, hazard ratio; HSCT, hematopoietic stem cell transplantation; OS, overall survival

A

OS

Fig. 2 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

OS

Fig. 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme jump
查看结果
KM Figure1 个面板

Fig. 4

Fig. 4 Kaplan-Meier analysis of EFS by treatment arm. P value is from a stratified 2-sided log-rank test. EFS rates and 95% CIs were estimated using the Kaplan-Meier method and Greenwood formula. CI, confidence interval; HR, hazard ratio; EFS, event-free survival

EFS

EFS

Fig. 4 · Panel EFS

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel EFS 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Patient disposition. Dispositions at the 30-day follow-up and long-term follow-up reflect patient status at this assessment date. Patients may have had different dispositions at the different assessments. SC, salvage chemotherapy
非 KM Figure
Fig. 3Fig. 3 Forest plot of overall survival subgroup analysis. An arrow is displayed for the 95% CI of the HR if the upper bound was greater than 3. An HR and 95% CI for all patients were based on a stratified Cox proportional hazard model with response to first-line AML therapy and preselected salvage chemotherapy per interactive response technology as stratification factors. In each subgroup, the HR and 95% CI were estimated using an unstratified Cox proportional hazard model. Assuming proportional hazards, an HR < 1 indicates a reduction in hazard rate in favor of the gilteritinib arm. AML, acute myeloid leukemia; CI, confidence interval; CRc, composite complete remission; ECOG PS, Eastern Cooperative Oncology Group performance status; FLT3, FMS-like tyrosine kinase 3; HR, hazard ratio; HSCT, hematopoietic stem cell transplantation; ITD, internal tandem duplication; NE, not estimable; TKD, tyrosine kinase domain
非 KM Figure
Fig. 5Fig. 5 Best overall response. CRc was defined as CR + CRi + CRp. ORR was defined as CRc + PR. All categories were mutually exclusive. CR, complete remission; CRc, composite complete remission; CRi, complete remission with incomplete hematologic recovery; CRp, complete remission with incomplete platelet recovery; NE, not estimable; NR, no response; ORR, overall response rate; PR, partial remission
非 KM Figure